The substantiation of market opportunities for domestic manufacturers in the segment of anti-inflammatory and anti-rheummatic medicines

Abstract

Goal is an analysis of the assortment of anti-inflammatory and anti-rheumatic medicines presented on the pharmaceutical market of Ukraine, and substantiation of market opportunities for domestic manufacturers. Materials and methods. The research materials are data from the State Register of Medicines of Ukraine and the online directory of medicines Compendium, publications of scientific and practically-oriented medical and pharmaceutical publications. The methods of office marketing research, comparative analysis, logical summarization of results, and the graphic method were used for achieving the goal. Results of the research. During the study, the structure of the assortment of anti-inflammatory and anti-rheumatic medicines and the characteristic trends for the registration of new medicines on the domestic pharmaceutical market were determined. It has been established that in 2022, 463 trade names will be registered on the domestic pharmaceutical market. The assortment of anti-inflammatory and anti-rheumatic medicines was analyzed by active substance, release form, producing countries, and the possibility of use in pediatrics. Prospective directions for updating the product assortment of anti-inflammatory and anti-rheumatic medicines of domestic production have been determined. Conclusions. According to the results of the study, it was found that the group of anti-inflammatory and anti-rheumatic medicines is represented by a wide assortment, however, the market is characterized by import dependence, which has a negative impact on the medical supply of certain categories of consumers. Prospective segments on the market of anti-inflammatory and anti-rheumatic medicines for domestic manufacturers have been established.